crsp rapidli develop platform
hemoglobinopathi oncolog rais pt
messag increas pt crsp base clinic
market entri timelin lead product hemoglobinopathi could
clinic market entri late -thal market entri scd
late believ crsp ahead gene edit compani
hemoglobinopathi also io space allogen car-t
final believ safeti efficaci concern rais yesterday
direct applic crsp ex vivo approach
stock later discuss crsp juno nv
word safeti human
yesterday stock price crispr crsp peer
pressur due paper publish biorxiv charlesworth et al paper
identifi pre-exist adapt immun protein human preexist
humor respons antibodi base respons convincingli demonstr
preexist cell respons point humor respons pose danger
crsp ex vivo approach human immun system
expos signific concern presenc cell respons
inde ex vivo approach gene edit via rnp decreas
exposur protein present mhc protein constitut express
usual degrad rather rapidli within cell believ half-lif long
enough make gene edit short enough minim mhc present simpl
workaround would cultur ex vivo edit cell suffici time interv
elimin trace amount inject human patient
recent public schaefer et al natur method rais concern
off-target mutat howev point view sever flaw
experiment design data interpret paper see previou note
scientif commun equal critic schaefer et al believ
combin silico guide-seq extens biolog evalu grna use
crsp suffic demonstr off-target activ detect furthermor
use crispr ex vivo rnp complex may lead shorten half-lif
protein compar viral deliveri believ rnp complex stabl enough
make cut short-liv enough make off-target cut
believ crsp ex vivo approach minim
even exclud mani safeti concern rais recent public furthermor
crsp vivo approach use mrna self-inactiv virus thu minim
express subsequ mhc present
crsp nutshel potenti catalyst-rich pipelin ahead
competit
crispr crsp announc public offer common share
last week see press releas remind vertex exercis opt-in
see previou note wherea crsp wholli own io portfolio
compani crsp exhibit dens timelin ind/cta file novel cut
edg crispr-bas therapeut ensu clinic trial cta file
complet clinic trial ph -thal eu expect begin
expect market entri late thu anticip crsp receiv
pedest gold medal marathon clinic out-sprint edita intellia
page analyst certif import disclosur
crsp plan submit ind ph
trial sickl cell diseas scd expect market entri late understand
also leverag crispr technolog hemoglobinopathi emphas
lag behind crsp acceler timelin admittedli percent increas
fetal hemoglobin background subtract appear three
compani surpris almost expect given grna somewhat
similar given sequenc constraint grna select enzym usag across
three compani
malign ind file expect clinic trial begin earli
given gilead yescarta timelin first-dos patient file approv
year one could assum file around mid potenti market entri late
indic view allo car-t potenti repres one
disrupt develop treatment paradigm cancer akin chemotherapi
blockad besid heme solid tumor well bcmc allo
car-t demonstr poc vivo lastli crsp multipl alreadi defin allo car-
ts solid tumor move closer poc vitro crispr technolog allow rapid
test multiplex car-t product advantag competitor use zinc finger
zfn talen gene edit employ sangamo cellecti respect
fact crsp research team requir less month foundat antibodi
poc vivo base rapid research timelin may expect
see vivo data throughout understand also leverag
crispr technolog car-t space howev best knowledg neither
shown preclin data develop allo car-t
furthermor note crsp allo car-t platform wholly-own wherea
enter collabor field juno
pictur high unmet medic need scd -thal
sickl cell diseas scd -thalassemia major -thal fall two larg subset
-globin gene mutat result either abnorm hemoglobin structur scd
significantli reduced/abs product -globin chain -thal heterozyg usual
asymptomat homozyg acut anemia aris variou form mutat within
-globin gene scd caus singl point mutat -globin gene
result format sickl hemoglobin hb clinic manifest
inherit disord typic appear sever month birth gene express
switch fetal -globin chain form fetal hemoglobin hbf adult
a-globin chain form hemoglobin hba current therapeut strategi
globin disord consist mainli lifelong regular red blood cell transfus howev
regular blood transfus lead iron overload relat complic iron
chelat therapi need administ order remov excess iron
definit cure present disord bone marrow transplant howev
numer complic associ procedur includ difficulti
find human leukocyt antigen hla -match donor graft-versus-host diseas
graft reject transplant conclus believ repres
potenti drastic chang treatment paradigm -thal scd see
page analyst certif import disclosur
hemoglobinopathi crispr
hemoglobin protein molecul red blood cell carri oxygen lung
bodi tissu return carbon dioxid tissu back lung thu
hemoglobin absolut essenti surviv hemoglobin express complex
tightli regul develop fetu -globin express high level pair
-globin form fetal hemoglobin hbf tetram shown exhibit
-globin express repress replac -globin month
age -globin pair -globin form hba tetram
thal caus mutat nondelet delet hemoglobin gene
thal major manifest allel affect patient -thal scd
becom symptomat hbf replac hba usual month
birth indic upregul hbf may viabl therapeut strategi
diseas persist fetal hemoglobin hpfh benign genet condit allow
continu express -globin adulthood usual hpfh asymptomat
hbf hba peac coexist howev patient suffer hemoglobinopathi
continu biosynthesi hbf may substitut miss faulti hba matter
fact hpfh show strong co-inherit pattern famili -thal mutat henc
name thu natur led way crsp show potenti treatment option
hemoglobinopathi whose etiolog explain -globin mutat simpli
upregul -globin increas hbf biosynthesi thu substitut hba
upregul achiev via crispr key understand
exhibit hemoglobinopathi crispr nutshel dynam express pattern
hemoglobin human within month birth -globin green rapidli replac
-globin blue mutat -globin caus hemoglobinopathi -thal
scd hpfh benign condit -globin continu express
vari percentag depend mutat homo- vs heterozygot hpfh
individu usual present asymptomat unless co-pres -thal scd
diseas hpfh may amelior sever hemoglobinopathi whose etiolog
mutat -globin crispr use mimic hpfh genet mutat increas
-globin patient suffer scd -thal compani report
genet culprit globin switch
transcript factor power regul repressor -globin express
shown act physiolog mediat switch hbf
hba indispens repressor -globin activ human bind
globin locu control region lcr multipl region -globin gene locu
regul globin express erythropoiesi multipl transcript factor
mediat -globin repress research group demonstr
hpfh mutat insid -globin gene region inhibit bind target
sequenc lead transcript -globin corrobor
subsequ studi mice model scd show knockdown
transgen scd mice stimul therapeut level hbf sever question
remain regard mechan hbf repress critic role may
har therapeut intervent substanti evid suggest presenc
multipl cis-act element specif enhanc region within -globin
locu hemoglobin switch hbf hba reconfigur -globin
cluster bind lcr distal enhanc element intergen region a-
globin -globin gene bind -globin -globin gene
upon bind promot format chromosom loop long-rang interact
page analyst certif import disclosur
lcr -globin gene expens lcr -- globin interact thu
promot transcript activ -globin silenc effect -globin
absenc conform -globin locu chang lcr
interact transcript activ -globin gene taken togeth knockout
mediat crispr technolog may benefici patient suffer
hemoglobinopathi re-express hbf symptomat patient howev
point known regul globin switch other
implic switch well less well character
ad complex scd also
work scd
wild-typ human a-globin rel weak inhibitor sickl hemoglobin hb
polymer simpli act dilut partial oxygen pressur
low capillari vessel phenylalanin leucin form acceptor
hydrophob pocket one tetram bind mutat valin
diseas caus point mutat close complex phenomenon respons
hb polymer hba hydrophob residu thu
inhibit polym format incorpor contrast human -like-globin
chain -globin -globin stronger inhibitor hpfh littl hbf
suffici inhibit hb format vivo allevi clinic manifest scd
homozyg scd patient case -chain exclud heterotetram
hb polym critic residu differ posit
determin respons inhibitori effect
-globin hb polymer taken togeth believ work
-thal also scd due natur presenc re-express -globin see
data look like far hemoglobinopathi
achiev allel edit human hematopoiet progenitor cell
hpc major show bi-allel edit bi-allel edit cell
globin ratio healthi donor cell ratio hbf/ hbf hba protein
background subtract healthi donor thu reach clinic meaning level
initi data two -thal patient edit cell show mrna ratio
-globin -globin ratio superior asymptomat -thal minor cell
diseas patient cell scd patient background subtract hbf/
hbf hba protein treat final also show
edit efficaci long-term hsc conclus believ
induc enough hbf re-express may translat transfus reduct
independ human patient
hemoglobinopathi competit
alreadi mention leverag crispr technolog similar
manner compar crsp howev point crsp lead
timelin among three compani experiment treatment
term lentiglobin alreadi clinic trial howev would like emphas
lentivir insert random inde preferenti gene region compar precis
cut may increas likelihood develop lymphoma
opinion term efficaci hard compar vs lentiglobin time
measur hbf lentiglobin measur g/dl mutant
remind crsp enter seri collabor io space
technolog may power tool crsp collabor agreement
massachusett gener hospit masthercel sa org
may help expand compani io program crispr neon
therapeut io compani develop neoantigen-bas therapeut vaccin cell
therapi treat cancer announc research collabor explor combin
compani proprietari technolog develop novel cell therapi june
crsp sign servic agreement develop manufactur allogen
cell therapi masthercel sa org agreement call develop
page analyst certif import disclosur
manufactur crsp lead io program masthercel sa cgmp
condit use futur clinic studi see previou note
believ crsp continu make inroad io space leadership
jon terrett head immuno-oncolog research translat
program crispr immuno-oncolog program advanc lead program
allogen car-t therapi engin off-the-shelf product
treatment posit malign program util crispr proprietari
gene-edit technolog make target modif t-cell therebi enabl
allogen off-the-shelf product applic broader patient popul
address challeng current gener autolog therapi crispr/
system engin specif multiplex edit shown efficaci
car-t cell abl elimin tumor pre-clin model
posit pre-ind meet fda end compani intend
file ind end clinic trial evalu expect
initi earli
novemb crispr present data first time develop
reduc gvhd potenti reduc reject potenti
malign see previou note believ off-the-shelf car-t could
disrupt checkpoint inhibit chemotherapi believ preclin studi
mous lymphoma leukemia model hold promis clinic success human
furthermor contract manufactur organ alreadi purifi off-the-
shelf car-t product enrich tcr delet cell tcr-
puriti crsp wholli own ip
present compani event opinion leader dr stephan grupp
emphas posit argument off-the-shelf product wait period
treatment less expens howev note off-the-shelf would
need show efficaci compar autolog ts rang
key would persist mhc knock-out could solv problem dr
grupp confirm allogen would highli disrupt autolog -t
believ one sophist program allogen
car-t space emphas crsp wholly-own ip io platform
intellectu properti
licens single-guid gene edit technolog non-cellular cellular
applic includ human cell crsp previous announc
compani grant receiv notic broad patent coverag china state
intellectu properti offic sipo well equival offic australia new
zealand singapor manag expect earli appeal decis occur sometim
believ ip litig continu play next two year
remind crispr along co-found crispr/
technolog appeal feder court appeal previou rule
patent trial appeal board ptab termin interfer two compet
patent claim claim relat gene-edit crispr patent held
broad institut mit edita univers california uc crsp/
intellia first invent use system eukaryot
cell origin ptab termin decis base premis respect
scope uc broad patent claim defin patent invent
uc crsp/ntla seek review revers decis unit state patent
trademark offic uspto expect issu patent vilniu
univers patent crsp hold sublicens human therapeut
applic direct use ribonucleoprotein rnp format
complementari compani foundat ip estat
univers california berkeley broad institut mit harvard
file separ patent direct access intellectu properti crispr
technolog intellia license univers california/
univers vienna edita license broad institut uc berkeley scientist
jennif doudna emmanuel charpenti first file crispr patent
page analyst certif import disclosur
march claim prioriti date may base paper publish
scienc mag jinek et al broad institut molecular biologist feng zhang
file patent applic octob claim prioriti date decemb
law time uc berkeley patent file patent grant
first parti invent march unit state patent trademark
offic enforc new law patent award first parti file zhang file
patent applic first-to-fil law came effect abl claim date
prior march file acceler examin request key patent
applic zhang receiv expedit review patent applic grant
first crispr patent april intellectu properti origin grant broad
institut find zhang
rais price target crispr increas price
target base faster pipelin progress previous anticip well
potenti market entri beta thalassemia late sickl cell diseas late
pt reflect probabl previous market entri
beta-thalassemia probabl sickl cell diseas remain model
indic receiv probabl market entri hurler syndrom scid dmd
gsd price target base dcf analysi use
discount rate previous reflect risk adjust made futur cash
due rapid advanc crsp pipelin shift market entri
crsp futur beta-th product late eu previous model market entri
late market entri late previous late
adjust risk-adjust revenu beta-th model
eu eu given rapid evolut beta-
thalassemia pipelin increas probabl market entri beta-th
shift entri compani sickl cell diseas scd
product late late late previous late
eu model risk-adjust scd revenu
account compani recent follow-on offer effect
result increas share count common share adjust
total oper revenu estim increas
includ continu revenu grants/contract model profit begin
estim ep
valuat risk
valuat price target base dcf analysi includ risk-
adjust model probabl market entri beta-thalassemia
probabl sickl cell diseas remain model indic receiv
probabl market entri crispr/ brought market model
assum rapid uptak across approv indic assum bolu
patient treat rel earli indic launch order reflect view
uptak potenti cur therapi patient becom treat assum
target assum profit begin ep estim valuat
deriv use discount rate previous termin growth rate
risk risk price target thesi includ limit neg clinic
trial result relat safeti efficaci crsp drug candid failur gain
eu regulatori approv emerg clinic result competit therapi challeng
crsp intellectu properti posit lower expect /ex sale
page analyst certif import disclosur
thousand except per-shar figur
develop licens agreement
grant contract
good
incom loss oper
loss equiti method invest
extinguish conv loan
unreal loss gain secur
net incom attribut sharehold
compani document guggenheim secur llc estim
page analyst certif import disclosur
